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Lynch syndrome 
Lynch syndrome/hereditary non- 
polyposis colon cancer fact sheet  
Clinical features 
Lynch syndrome (LS) is caused by a mutation in a mismatch repair (MMR) gene. Individuals with 
LS are at increased risk for colon and other cancers, including gastric, urinary tract, brain, small 
bowel, pancreatic, hepatobiliary and sebaceous carcinoma. Women with LS are at increased risk for 
endometrial and ovarian cancer.
Diagnosis of LS
An individual should meet Amsterdam II criteria or have a mutation that is identified by molecular 
genetic testing of the MMR genes.
Clinical diagnosis of LS: The Amsterdam II criteria define the minimum requirements for a clinical 
diagnosis of Lynch syndrome.
There should be at least three relatives with a Lynch/HNPCC-associated cancer (cancer of the colorectum, 
endometrium, small bowel, ureter or renal pelvis) and … 
• One should be a first-degree relative to the other two
• At least two successive generations should be affected
• At least one should be diagnosed before age 50
• Familial adenomatous polyposis should be excluded




 Mismatch repair genes 
MLH1 & MSH2 (mutation present in about 90 percent of LS families) 
MSH6 (mutation present in about 7–10 percent of LS families) 
PMS2 (mutation present in <5 percent of LS families)
Non-mismatch repair genes
EPCAM (mutation present in 1–3 percent of LS families)
Genetic testing  
Direct gene testing is available commercially. To identify colorectal cancer patients who may 
have LS, the current recommendations are to begin by ordering microsatellite instability (MSI) or 
immunohistochemistry (IHC) testing on the tumor sample. This can be performed by a pathologist 
on archived tumor blocks from a surgical specimen. These tests detect either an increased number of 
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Lynch syndrome 
microsatellite repeats (MSI, a hallmark of impaired mismatch repair gene activity), or the absence of 
the protein products of the mismatch repair genes (IHC). MSI/IHC have known utility for colorectal 
and endometrial cancers but are not routinely recommended for other cancers. If either test is 
positive, meaning that the mismatch repair genes appear to be impaired, then continue on to genetic 
testing that can determine which mismatch repair gene is mutated. Whenever possible, begin this 
genetic testing on an affected family member. The identification of a mutation confirms the diagnosis 
of LS. If a mutation is not identified, a diagnosis of LS can neither be confirmed nor ruled out; this 
result must be interpreted in the context of the patient’s MSI/IHC results, family and personal history 
and test limitations. See “Overview of testing for Lynch syndrome tool” for more information.
Colon cancer risk
General population Lynch syndrome Mean age at cancer 
onset (LS)
Male 5.6% 28–75%* 44–61 years
Female 5.3% 24–52%* 44–61 years
*lower risks w/MSH6, PMS2 gene mutations
Associated cancer risks*
Type of cancer General population Lynch syndrome Mean age at cancer 
onset (LS)
Endometrium 2.7% 27–71% 46–62 years








*Increased risks for additional primary colon cancers
Non-cancer findings: keratoacanthomas, sebaceous adenomas
Screening recommendations (See “Screening guidelines tool”): 
1.  Colonoscopy: every one to two years starting at age 20–25 or two to five years prior to the 
earliest colon cancer in the family if diagnosed under age 25.  
2.  If colon cancer is found, consider removal of entire colon and continue annual screening for 
rectal cancer.  
3.  Consider prophylactic removal of the colon in cases where regular screening with colonoscopy 
cannot be performed.  
4. Females: consider annual endometrial sampling and transvaginal ultrasound.
5.  Consider prophylactic hysterectomy with bilateral salpingo-oophorectomy after childbearing 
is complete.
6. Consider annual urinalysis. 
7.  Consider EGD with extended duodenoscopy and polypectomy at two to three year intervals 
beginning at age 30.
Screening references:
NCCN Colorectal Cancer Screening Guidelines, V.2.2011.  
nccn.org/professionals/physician_gls/f_guidelines.asp
ACG Guidelines for Colorectal Cancer Screening 2009.  
http://s3.gi.org/physicians/guidelines/CCSJournalPublicationFebruary2009.pdf
Vasen, H., Watson, P., Mecklin, J.-P., & Lynch, H. (1999). New clinical criteria for hereditary nonpolyposis colorectal cancer 
(HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology, 116(6), 1453–1456.
 
Adapted from Genetics in the Physician Assistance’s Practice 
 
 
Inherited Thrombophilia Fact Sheet 
 
Inherited thrombophilia is a genetic tendency toward venous thromboembolism (VTE) the usually 
presents in patients under age 50 and is often recurrent. 
 
The most frequent causes are mutations of Factor V Leiden or prothrombin genes, which account for 50 
to 60 percent of cases. Other defects in protein S, protein C, and antithrombin (i.e. antithrombin III) 
account for most of the rest. 
 
About 50% of the VTE events in patients with inherited thrombophilia have an acquired risk factor, such 
as smoking, oral contraceptive use, recent surgery, or pregnancy. 
 
Genetic causes of thrombophilia  
Mechanism/factor Population Prevalence Inheritance Pattern Risk of VTE by Age 60 
Deficiency of anticoagulants 
Antithrombin III < 1% Autosomal dominant 60% 
Protein C < 1% Autosomal dominant 50% 
Protein S 1% Autosomal dominant 33% 
 
Mechanism/factor Population Prevalence Inheritance Pattern Lifetime Risk of VTE 
Increased procoagulants 
Factor V Leiden 3-7% Autosomal dominant 5-20% 
Prothrombin G20210A 1-4% Autosomal dominant 10-20% 
Elevated homocysteine 10-15% Multifactorial Not yet determined 
Adapted from Up To Date 
 
 
Genetic Diagnostic Testing and Presymptomatic Testing 
 
Genetic diagnostic testing is done when a patient is offered a genetic test based on symptoms and signs 
already present. The purpose is to rule out a genetic cause of current symptoms. 
 
Presymptomatic testing is when an at-risk individual, who is asymptomatic at the time, carries a mutant 
gene that may increase the risk of developing disease at some point in the future. Typically, an effected 
family member has had a positive genetic diagnostic test. 
 
“Red Flags” Suggesting Inherited Thrombophilia 
 
Recurrent VTE, or spontaneous VTE 
VTE at a young age 
Recurrent miscarriage 
Thrombosis in unusual sites (e.g. sagittal sinus) or multiple thrombi 
Coronary or cerebral thrombosis at an early age (Men < 50, Women < 60) 
